Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04150614 · ClinicalTrials.gov registry record · Phase 4
BMT-08: A Comparative Effectiveness Study of Transdermal Granisetron to Ondansetron
A Phase 4 study of Nausea With Vomiting Chemotherapy-Induced, sponsored by University of Illinois at Chicago.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 90
- Enrollment target
- 1
- Study location
NCT04150614: Recruiting Phase 4 study of Nausea With Vomiting Chemotherapy-Induced, sponsored by University of Illinois at Chicago.
NCT04150614 is a Phase 4 study of Nausea With Vomiting Chemotherapy-Induced that is actively recruiting participants, run by University of Illinois at Chicago. The registered enrollment target is 90 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04150614, a Phase 4 study of Nausea With Vomiting Chemotherapy-Induced, is actively recruiting participants, sponsored by University of Illinois at Chicago.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 90 participants
- Enrollment target
- 1
- Study location
Study Summary
Patients undergoing either an autologous or allogeneic hematopoietic stem cell transplant (HSCT) and receiving preparative chemotherapy experience a considerable amount of chemotherapy-induced nausea and vomiting (CINV). Current strategies at reducing CINV in this patient population are suboptimal due to lack of efficacy and supportive evidence, potential for increased adverse events, and drug-drug and drug-disease contraindications.
Primary Outcome
Efficacy of Ondansetron and Dexamethasone versus Transdermal Granisetron and Dexamethasone in preventing chemotherapy induced nausea and vomiting during the acute period (0 - 24 hours post-chemotherapy) for patients receiving preparative chemotherapy and HSCT.
Conditions Studied
Interventions
- DRUG Ondansetron
- DRUG Granisetron Transdermal Patch
- DRUG Intravenous Dexamethasone
Study Locations (1)
Illinois
- University of Illinois Cancer Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2020-05-14 |
| Est. Completion | 2026-07 |
| Phase | Phase 4 |
What NCT04150614 shows while recruiting
NCT04150614 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (83% lower).
The record links to 1 condition, with Nausea With Vomiting Chemotherapy-Induced appearing as the primary indexed condition, and to 3 interventions - of which Ondansetron is the first listed.
NCT04150614 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT04150614 about?
NCT04150614 is a clinical study titled "BMT-08: A Comparative Effectiveness Study of Transdermal Granisetron to Ondansetron". Patients undergoing either an autologous or allogeneic hematopoietic stem cell transplant (HSCT) and receiving preparative chemotherapy experience a considerable amount of chemotherapy-induced nausea and vomiting (CINV). Current strategies at reducing CINV in this patient population are suboptimal d...
What is the current status of trial NCT04150614?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 90 participants. The study started on 2020-05-14. Estimated completion is 2026-07.
What conditions does trial NCT04150614 study?
This clinical trial studies the following conditions: Nausea With Vomiting Chemotherapy-Induced.
What interventions are being tested in trial NCT04150614?
The interventions under investigation include: Ondansetron (DRUG), Granisetron Transdermal Patch (DRUG), Intravenous Dexamethasone (DRUG).
Who is sponsoring clinical trial NCT04150614?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04150614 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04150614's enrollment target sits among peer trials
90 886th of 2000 higher than 1,089 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI